SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET.
康涅狄格州斯坦福，2024年5月8日（GLOBE NEWSWIRE）——专注于严重罕见疾病和癌症的商业阶段生物制药公司SpringWorks Therapeutics, Inc.（纳斯达克股票代码：SWTX）今天宣布，管理层将参加太平洋时间2024年5月14日星期二下午3点40分在内华达州拉斯维加斯举行的美国银行证券2024年医疗保健会议的炉边谈话美国东部时间下午
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company's website at A replay of the webcast will be available on SpringWorks' website for a limited time following the conference.
要观看网络直播，请访问公司网站 “投资者与媒体” 部分中的 “活动和演讲” 页面。会议结束后，网络直播的重播将在SpringWorks的限定时间内在SpringWorks的网站上播出。
About SpringWorks Therapeutics
关于 SpringWorks 治疗公司
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.
SpringWorks是一家处于商业阶段的生物制药公司，采用精准医疗方法为患有严重罕见疾病和癌症的人开发和提供改变生活的药物。
Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers. OGSIVEO, approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is SpringWorks' first FDA-approved therapy. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its lead product candidates into late-stage trials and enter into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
SpringWorks成立于2017年，拥有多元化的靶向肿瘤产品线，涵盖实体瘤和血液系统癌，包括针对罕见肿瘤类型和高度流行的基因定义癌症的临床试验。OGSIVEO是SpringWorks首款经美国食品药品管理局批准的疗法，已获美国批准用于治疗需要全身治疗的硬结肿瘤进展的成年患者。SpringWorks的战略方针和临床开发方面的卓越运营使其能够迅速将其主要候选产品推向后期试验，并与行业和学术界的创新者进行多次合作，以释放其产品组合的全部潜力，为癌症患者创造更多解决方案。
For more information, visit and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
欲了解更多信息，请访问 然后关注 @SpringWorksTx 在 X（前身为 Twitter）上， 领英，以及 优酷。
Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
联系人：
金戴蒙德
传播与投资者关系副总裁
电话：203-561-1646
电子邮件： kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com
萨曼莎·希尔森·桑德勒
投资者关系高级董事
电话：203-461-5501
电子邮件： samantha.sandler@springworkstx.com
译文内容由第三方软件翻译。